公开(公告)号：US20180312507A1

公开(公告)日：2018-11-01

申请号：US15965172

申请日：2018-04-27

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Subramanian KARUR ,  Peichao LU ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D405/12 ,  C07D401/12 ,  C07D491/16 ,  A61P31/12

CPC classification number: C07D471/14 ,  A61K31/4985 ,  A61K45/06 ,  A61P31/12 ,  C07D401/12 ,  C07D405/12 ,  C07D471/22 ,  C07D491/16

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20190300530A1

公开(公告)日：2019-10-03

申请号：US16383382

申请日：2019-04-12

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Subramanian KARUR ,  Peichao LU ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D401/12 ,  C07D491/16 ,  A61P31/12 ,  A61K45/06 ,  C07D471/22 ,  A61K31/4985 ,  C07D405/12

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20180030053A1

公开(公告)日：2018-02-01

申请号：US15782722

申请日：2017-10-12

Applicant: Novartis AG

Inventor： Jiping FU ,  Xianming JIN ,  Patrick LEE ,  Peichao LU ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D491/147 ,  A61K31/4375

CPC classification number: C07D471/14 ,  A61K31/4375 ,  C07D217/08 ,  C07D491/14 ,  C07D491/147

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20170240548A1

公开(公告)日：2017-08-24

申请号：US15435137

申请日：2017-02-16

Applicant: Novartis AG

Inventor： Jiping FU ,  Xianming JIN ,  Patrick LEE ,  Peichao LU ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D491/147 ,  A61K31/4375

CPC classification number: C07D471/14 ,  A61K31/4375 ,  C07D217/08 ,  C07D491/14 ,  C07D491/147

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20170217897A1

公开(公告)日：2017-08-03

申请号：US15500870

申请日：2015-08-03

Applicant: Zhigan JIANG ,  Jianhua XIA ,  Haiying HE ,  NOVARTIS AG

Inventor： Javier de Vicente FIDALGO ,  Haiying HE ,  Cheng HU ,  Zhigan JIANG ,  Xiaolin LI ,  Peichao LU ,  Wosenu MERGO ,  Daniel MUTNICK ,  Folkert RECK ,  Alexey RIVKIN ,  Colin Keith SKEPPER ,  Xiaojing Michael WANG ,  Jianhua XIA ,  Yongjin XU

IPC: C07D215/38 ,  A61K31/4709 ,  A61K31/496 ,  C07D401/14 ,  C07D413/14 ,  C07D419/14 ,  C07D405/14 ,  C07D471/04 ,  C07D498/10 ,  A61K31/5377 ,  A61K31/5386 ,  C07D487/10 ,  C07D471/10 ,  A61K45/06 ,  C07D401/04

CPC classification number: C07D215/38 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/5386 ,  A61K45/06 ,  C07D215/22 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D419/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/10 ,  C07D498/10 ,  Y02A50/406 ,  Y02A50/47 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481

Abstract: This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit bacterial gyrase. The compounds are useful as inhibitors of bacterial gyrase activity and bacterial infections, and have the structure of Formula (I) as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.

公开(公告)号：US20200270265A1

公开(公告)日：2020-08-27

申请号：US15999664

申请日：2017-02-16

Applicant: Novartis AG

Inventor： Jiping FU ,  Xianming JIN ,  Patrick LEE ,  Peichao LU ,  Joseph Michael YOUNG

IPC: C07D491/147 ,  C07D471/04 ,  C07D519/00 ,  A61P31/20

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20200270252A1

公开(公告)日：2020-08-27

申请号：US16808985

申请日：2020-03-04

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Subramanian KARUR ,  Peichao LU ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D405/12 ,  A61P31/12 ,  C07D491/16 ,  C07D401/12 ,  A61K45/06 ,  A61K31/4985 ,  C07D471/22

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.